UCSF School of Medicine

The UCSF School of Medicine strives to advance human health through a fourfold mission of education, research, patient care and public service.

https://www.ucsf.edu/

 

Insights from ESMO Breast 2024 Annual Meeting
H

ESMO Breast 2024 Insights: "TROPION-Breast01 Additional Safety Analysis - Dato-DXd vs. Chemo in Pretreated, Inoperable/Metastatic HR+/HER2- BC"

By Insights from ESMO Breast 2024 Annual Meeting FEATURING Hope Rugo
By Insights from ESMO Breast 2024 Annual Meeting FEATURING Hope Rugo
347 views
May 20, 2024
0 Comments
Login to view comments. Click here to Login
Oncology & Hematology
08:49
2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-…

Feat. K. Natsuhara
26:22
UCSF School of Medicine

Best of ASCO® 2024: Myeloma Highlights and Practice Impacts

Feat. A. Chari
25:09
UCSF School of Medicine

Integrative Medicine Approaches for Patients With Primary CNS Tumors

Feat. N. Butowski
09:34
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Impact of ctDNA Surveillance on Clinical …

Feat. M. Lipsyc-Sharf
09:40
UCSF School of Medicine

Trastuzumab Deruxtecan Approval for Metastatic HER2+ Bladder Cancer

Feat. V. Koshkin
36:18
Insights from ESMO Breast 2024 Annual Meeting

Metastatic Breast Cancer Comprehensive Review: ESMO Breast 2024 Awar…

Feat. H. Rugo
10:09
Insights from ESMO Breast 2024 Annual Meeting

ESMO Breast 2024 Insights: "Pooled Analysis of T-DXd Retreatmen…

Feat. H. Rugo
07:29
Insights from ESMO Breast 2024 Annual Meeting

ESMO Breast 2024 Insights: "CAPItello-291 Trial PFS2 & TFSC…

Feat. H. Rugo
11:03
Insights from ESMO Breast 2024 Annual Meeting

ESMO Breast 2024 Insights: "TROPION-Breast01 Additional Safety …

Feat. H. Rugo
30:03
UCSF School of Medicine

Recent Advances in Advanced Urothelial Cancers: Time for a New Stand…

Feat. T. Friedlander
04:18
Insights from 2023 SABCS

SABCS 2023 Insights: "Comparison of NGS Results From the Cerebr…

Feat. L. Huppert
05:48
Insights from 2023 SABCS

SABCS 2023 Insights: "Sequential Use of ADCs T-DXd & SG in …

Feat. L. Huppert
11:05
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Alliance A051301/BMT-CTN 1201 Study - Ibrut…

Feat. C. Andreadis
09:46
Insights from 2023 SABCS

SABCS 2023 Insights: "ELEVATE Study Evaluating Elacestrant in V…

Feat. H. Rugo
14:15
Insights from 2023 SABCS

SABCS 2023 Insights: "KEYLYNK-009 Study - Pembro + Olaparib vs.…

Feat. H. Rugo
08:24
Insights from 2023 SABCS

SABCS 2023 Insights: "PROs From the CAPItello-291 Trial Investi…

Feat. H. Rugo
19:22
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: BCMA/GPRC5D/FcRH5 - CARs/BsAbs - How to Choose in R/R MM

Feat. A. Chari
22:17
Insights from 2023 IMS Annual Meeting

IMS 2023 Insights: "Unraveling the Myeloma Proteome"

Feat. A. Wiita
07:52
ASCO GU 2023 Conference Coverage

Independent Biomarkers Predictive of Outcomes With Enfortumab Vedoti…

Feat. T. Jindal
13:15
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Biomarkers Predicting Response to 5 IO Ar…

Feat. D. Wolf
09:18
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Enfortumab Vedotin +/- Pembro in Pts Who …

Feat. T. Friedlander
07:49
ESMO Breast Cancer 2023 Congress Coverage

ESMO Breast Cancer 2023 KEYNOTE-355 Trial: Outcomes in TNBC Patients…

Feat. H. Rugo
17:44
ESMO Breast Cancer 2023 Congress Coverage

ESMO Breast Cancer 2023 Phase 3 DESTINY-Breast04 Trial Safety Analys…

Feat. H. Rugo
09:05
AACR 2023 Conference Coverage

AACR 2023 on KEYNOTE-966 Phase 3 Study: Pembro in Combination With G…

Feat. K. Kelley
06:47
UCSF School of Medicine

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+…

Feat. H. Kang
03:32
UCSF School of Medicine

Management of Abemaciclib-Related Diarrhea in HR+/HER2- eBC

Feat. S. Donahue
05:39
ASCO GU 2023 Conference Coverage

ASCO GU 2023 Analysis of the UNITE Study: Biomarkers of Response to …

Feat. T. Jindal
10:28
UCSF School of Medicine

IO vs. Targeted Therapy as Adjuvant Treatment in BRAFm Advanced Mela…

Feat. A. Daud
08:41
ASH 2022 Conference Coverage

ASH 2022 Long-Term Outcomes of Patients With TDT Followed Up to 8 Ye…

Feat. M. Walters
11:43
UCSF School of Medicine

CARTITUDE-1: 2 Years Post-LPI Update on the Phase 1b/2 Study of Cilt…

Feat. T. Martin
47
UCSF School of Medicine

Lecture Summary - Impact of Primary Tumor Location on OS and PFS in …

Feat. A. Venook
15:07
UCSF School of Medicine

Impact of Primary Tumor Location on OS and PFS in Patients with mCRC…

Feat. A. Venook
15:00
UCSF School of Medicine

Ongoing Clinical Trials and Future Directions in Advanced Urothelial…

Feat. V. Koshkin
20:17
UCSF School of Medicine

ESMO 2021 Updates on 1L Pembro + Chemo vs. Placebo + Chemo for mTNBC…

Feat. H. Rugo
09:20
UCSF School of Medicine

ESMO 2021 Post Hoc Analyses from PALOMA-2 and PALOMA-3: Effect of Pa…

Feat. H. Rugo
05:01
UCSF School of Medicine

ctDNA-Guided Treatment Strategy: How to Apply in Clinical Practice?

Feat. A. Venook
13:13
UCSF School of Medicine

ASCO 2021 Updates on Lisinopril or Carvedilol in Prevention of Trast…

Feat. P. Munster
04:37
UCSF School of Medicine

ASCO 2021 Update: Comparing Cilta-Cel in CARTITUDE-1 vs. Real-World …

Feat. T. Martin
11:08
UCSF School of Medicine

ASCO 2021 Updates on EV-103: Durability Results and Long-Term Outcom…

Feat. T. Friedlander
15:52
UCSF School of Medicine

ASH 2020 IKEMA Trial Update on Isatuximab in R/R MM: Should We Consi…

Feat. T. Martin